Firehawk® Rapamycin Target Eluting Coronary Stent System

Product Introduction

Firehawk® Rapamycin Target Eluting Coronary Stent System is the World's First and Only Target Eluting Stent (TES), which is the new generation product of Shanghai MicroPort Medical (Group) Co., Ltd. following the Firebird and Firebird2 stent to treat coronary artery stenosis or occlusion disease.


Adopted the platform of TES Technology®
Coating exposed area is only 5% of the stent surface
Drug in-vivo released over 90 days
Polymer fully absorbed in 9 months
Average Metal Coverage Rate14.0-16.1%
World's lowest drug dosage stent, with only 1/3 dosage versus similar products while achieving the same efficacy


stent diameter stent length
13 16 18 21 23 26 29 31 33 35 38
2.25 RV2213 RV2216 RV2218 RV2221 RV2223 RV2226 RV2229 - - - -
2.5 RV2513 RV2516 RV2518 RV2521 RV2523 RV2526 RV2529 RV2531 RV2533 - -
2.75 RV2713 RV2716 RV2718 RV2721 RV2723 RV2726 RV2729 RV2731 RV2733 RV2735 RV2738
3.0 RV3013 RV3016 RV3018 RV3021 RV3023 RV3026 RV3029 RV3031 RV3033 RV3035 RV3038
3.5 RV3513 RV3516 RV3518 RV3521 RV3523 RV3526 RV3529 RV3531 RV3533 RV3535 RV3538
4.0 RV4013 RV4016 RV4018 RV4021 RV4023 RV4026 RV4029 RV4031 RV4033 RV4035 RV4038